<DOC>
	<DOCNO>NCT01146054</DOCNO>
	<brief_summary>This multi-institutional trial aim evaluate potential benefit side effect add fractionate stereotactic body radiotherapy/surgery ( SBRT ) chemotherapy gemcitabine locally advanced pancreatic cancer .</brief_summary>
	<brief_title>Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy Unresectable Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>3.1.1 Histologically confirm adenocarcinoma pancreas . 3.1.2 Unresectable disease determine pancreatic cancer surgeon assessment GI oncology tumor board ( JHU , SU , MSKCC ) . 3.1.3 Up 3 week gemcitabine chemotherapy allow prior SBRT . 3.1.4 Pancreatic tumor must less 7.5 cm great axial dimension ( &lt; 1000 cc volume ) time treatment planning . 3.1.5 No prior upper abdominal liver radiation therapy . 3.1.6 No chemotherapy within 2 week radiotherapy , chemotherapy within parameter set Investigator institution . 3.1.7 Age &gt; =18 year . 3.1.8 No infection require systemic antibiotic treatment . 3.1.9 Karnofsky &gt; = 70 % ( see Appendix III ) . 3.1.10 Patients must acceptable organ marrow function define ( within 1 month prior radiotherapy ) : leukocyte : &gt; =3,000/uL absolute neutrophil count : &gt; =1,500uL platelet : &gt; =100,000/uL total bilirubin : within 1.5X normal institutional limit AST ( SGOT ) /ALT ( SGPT ) : &lt; =2.5 X institutional upper limit normal creatinine : within normal institutional limit OR creatinine clearance : &gt; =60 mL/min/1.73 m^2 patient creatinine level institutional normal 3.1.11 The effect radiation develop human fetus recommend therapeutic dos result death fetus . If woman childbearing potential , negative urine serum pregnancy test must demonstrate prior treatment . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) duration study participation 4 week follow study . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 3.1.12 Ability understand willingness sign write informed consent document . 3.1.13 Life expectancy &gt; 6 month 3.2.1 Patients prior radiotherapy upper abdomen . 3.2.2 Patients receive 1 cycle gemcitabine chemotherapy therapy prior SBRT . 3.2.3 Children exclude pancreatic tumor rarely occur age group . Furthermore , treatment require great deal patient cooperation include ability lie still several hour isolated room . 3.2.4 No laboratory personnel include . 3.2.5 Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 3.2.6 Any concurrent malignancy nonmelanoma skin cancer , noninvasive bladder cancer , carcinoma situ cervix . Patients previous malignancy without evidence disease &gt; 5 year allow enter trial . 3.2.7 Pregnant breastfeed woman exclude . Women childbearing potential unwilling unable use acceptable method birth control avoid pregnancy entire study period 4 week study exclude . This apply woman experience menarche undergone successful surgical sterilization postmenopausal ( define amenorrhea least 12 consecutive month , woman hormone replacement therapy serum FSH level great 35 mIU/mL . A negative urine serum pregnancy test must obtain within 72 hour prior start study medication woman childbearing potential . Male subject must also agree use effective contraception period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>